DNER and prostate cancer: Identification of BET inhibitors as a new vulnerability of FPC was an unexpected finding because many epigenetic drugs including BET inhibitors were used to induce a “BRCAness” phenotype and exert a synergistic cytotoxicity effect in combination with olaparib in HR-proficient tumors, including breast, ovarian and prostate cancers [36].